Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,610 JPY | +0.50% | +2.84% | +12.96% |
Apr. 12 | Penumbra, Inc. : The underdog in healthcare | |
Mar. 18 | Frontier Field Co., Ltd. announced that it has received funding from Terumo Corporation | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 35.97 and 31.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.31 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.96% | 24.62B | A- | ||
-2.31% | 187B | C+ | ||
-3.20% | 106B | C | ||
-5.04% | 66.9B | A | ||
+0.20% | 49.45B | B- | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.36% | 26.25B | A- | ||
+2.07% | 26.48B | B | ||
-1.93% | 24.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4543 Stock
- Ratings Terumo Corporation